Can IVZ sustain its Q3 earnings growth in 2025?

**Invesco's (IVZ) ability to sustain its Q3 earnings growth in 2025 is uncertain and depends on several factors.** Here's an analysis based on current financial data and market trends:

1. **Current Financial Performance**: Invesco's Q3 2024 financial results showed a diluted EPS of $0.12 and an adjusted diluted EPS of $0.44. This performance reflects the company's resilience amidst market volatility.

2. **Market Conditions**: The Capital Markets industry is crucial for economic development and contributes to growth and innovation. However, it is subject to market fluctuations and regulatory changes that can impact profitability.
3. **Economic Trends**: The overall economic environment, including interest rates, market volatility, and investor sentiment, can significantly affect investment banking and brokerage revenues. For Invesco, the rise in compensation and marketing costs could impact profitability.
4. **Strategic Initiatives**: Invesco's cost-saving initiatives and platform leverage could positively influence its financial performance. The company's ability to continue implementing efficient strategies will be key to sustaining growth.
5. **Comparative Analysis**: Raymond James Financial, Inc. (RJF) faced a 28% decline in net revenues in the Capital Markets segment for Q3 2023, primarily due to lower investment banking and fixed income brokerage revenues. This comparison suggests that Invesco's performance relative to industry peers is crucial for predicting its future growth.
6. **Industry Outlook**: The Capital Markets industry is expected to evolve, with policy makers focusing on improving market functioning and supporting sustainable growth. This suggests that regulatory changes could either support or challenge Invesco's growth trajectory.

In conclusion, while Invesco has shown signs of resilience and growth potential, the sustainability of its Q3 earnings in 2025 will depend on its ability to navigate market challenges, capitalize on strategic initiatives, and adapt to regulatory changes. Investors should monitor these factors closely to assess IVZ's future performance.